Analysts have raised their price target for Fosun International from $5.31 to $5.54, citing modest adjustments in forward valuation metrics as well as updated profitability expectations.
What's in the News
- Fosun International Limited will hold a Special or Extraordinary Shareholders Meeting on October 23, 2025, in Shanghai to seek approval for the adoption of the 2025 H share RSU scheme of Fosun Pharma. This is pending further approval by Fosun Pharma shareholders (Key Developments).
- The company has completed the repurchase of 41,310,000 shares, representing 0.51% of shares, for HKD 169.82 million as part of its buyback program announced on August 29, 2024. A total of 31,082,500 shares were repurchased between January 1 and June 5, 2025 (Key Developments).
- A Board Meeting is scheduled for August 27, 2025, to review the interim results for the first half of 2025 and consider the payment of an interim dividend (Key Developments).
Valuation Changes
- Fair Value Estimate has risen slightly from HK$5.31 to HK$5.54.
- Discount Rate remains virtually unchanged at 12.89%.
- Revenue Growth projection is stable and remains at approximately 7.5% year-over-year.
- Net Profit Margin has fallen marginally from 2.94% to 2.81%.
- Future P/E ratio has increased from 8.56x to 9.33x. This indicates a modest shift in valuation expectations.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.